Literature DB >> 8540971

When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?

R W Spingarn1, J A Berlin, B L Strom.   

Abstract

PURPOSE: To evaluate the educational effect on residents of a grand rounds given by a pharmaceutical company employee.
METHOD: Using a retrospective cohort study design, the authors questioned 75 housestaff at a university hospital three months after a February 1990 grand rounds on Lyme disease to determine whether the residents' beliefs about the drug of choice for this disease differed between attendees and non-attendees. Odds ratios, 95% confidence intervals, and logistic regression were used for the analysis of results.
RESULTS: The 22 housestaff who had attended the grand rounds were more likely to choose appropriately the cephalosporin manufactured by the speaker's company over other drugs for patients with Lyme disease presenting with second-degree heart block (adjusted odds ratio of 8.4; 95% CI 2.1-38.9). However, they also chose it inappropriately for first-degree heart block (adjusted odds ratio of 7.8; 95% CI 1.6-45.5). None of the attendees, compared with 11 (21%) of the non-attendees, named an oral antibiotic for both of two milder presentations, even though oral therapy would be more appropriate (p = .027).
CONCLUSION: The results suggest that grand rounds effectively change residents' beliefs, but a sponsoring company's drug may be favored. Information assimilated in this way may not be well supported by the scientific literature and could result in a choice of treatment that is more expensive than other acceptable treatments.

Entities:  

Mesh:

Year:  1996        PMID: 8540971     DOI: 10.1097/00001888-199601000-00022

Source DB:  PubMed          Journal:  Acad Med        ISSN: 1040-2446            Impact factor:   6.893


  10 in total

Review 1.  Interactions between pharmaceutical representatives and doctors in training. A thematic review.

Authors:  Daniella A Zipkin; Michael A Steinman
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

2.  A question of method. The ethics of managing conflicts of interest.

Authors:  Samia A Hurst; Alex Mauron
Journal:  EMBO Rep       Date:  2008-02       Impact factor: 8.807

3.  Drug companies and information about drugs: recommendations for doctors. Characteristics of materials distributed by drug companies: four points of view.

Authors:  C S Landefeld; M M Chren
Journal:  J Gen Intern Med       Date:  1996-10       Impact factor: 5.128

Review 4.  What information do physicians receive from pharmaceutical representatives?

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1997-05       Impact factor: 3.275

Review 5.  Can we make grand rounds "grand" again?

Authors:  Shaifali Sandal; Michael C Iannuzzi; Stephen J Knohl
Journal:  J Grad Med Educ       Date:  2013-12

6.  Professional Conferences, Unprofessional Conduct.

Authors:  A C Anand
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Public perceptions of physician - pharmaceutical industry interactions: a systematic review.

Authors:  Janine Arkinson; Anne Holbrook; Wojciech Wiercioch
Journal:  Healthc Policy       Date:  2010-05

Review 8.  Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.

Authors:  Geoffrey K Spurling; Peter R Mansfield; Brett D Montgomery; Joel Lexchin; Jenny Doust; Noordin Othman; Agnes I Vitry
Journal:  PLoS Med       Date:  2010-10-19       Impact factor: 11.069

9.  Turkish Final Year Medical Students' Exposure to and Attitudes Concerning Drug Company Interactions: A Perspective from a Minimally Regulated Environment for Medical Students.

Authors:  Nazim Ercument Beyhun; Cevriye Ceyda Kolayli; Gamze Can; Murat Topbas
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

Review 10.  Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.

Authors:  Freek Fickweiler; Ward Fickweiler; Ewout Urbach
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.